Laura Joszt, MA

The Virginia Center for Health Innovation (VCHI) is receiving a $2.2 million grant from Arnold Ventures to launch a 3-year statewide pilot to reduce the use of low-value care in the state of Virginia.

Minimal residual disease (MRD) testing is the future of diagnostics and monitoring for cancer, according to some experts. Not only can MRD determine the depth of response to a treatment, but it can also be used to determine treatment strategies.

Pediatric multiple sclerosis (MS) represents a small minority of MS diagnoses. WIth symptoms that differ from adults, children with MS often experience delays before they are diagnosed.

Interventions to prevent job loss for patients with multiple sclerosis (MS) should focus on increasing self-efficacy, especially for patients older than 50 years.

Costs remain the top concern of healthcare purchasers of pharmacy benefits, but employers are also concerned with ensuring appropriate use of medication and adherence to medication, according to a new report from the Pharmacy Benefit Management Institute (PBMI).

While use of palliative care at the end of life has increased, disparities remain, and not all patients who are terminally ill with blood cancers are having discussions about their goals of care at the end of life.

Two abstracts presented at the Transplantation and Cellular Therapy Meetings analyzed the detection of minimal residual disease during and after hematopoietic stem cell transplantation.

Low-value care that offers no benefit to patients, or can actually cause more harm than good, is costly to patients and the healthcare system. While low-value services are being identified and measured, it has been more difficult to reduce the use of low-value care.

Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.

Nearly 10% of drug approvals in 2018 were generic products for branded drugs that had no FDA-approved generics.

A new study determines the smallest change in upper extremity function that patients with multiple sclerosis (MS) find important or meaningful through an analysis in the change of scores of the Arm Functiom in Multiple Sclerosis Questionnaire.

A high proportion of patients with acute myeloid leukemia (AML) who achieve a negative minimal residual disease (MRD) status still relapse, indicating a more sensitive method of detecting MRD is needed.

Updates on the Oncology Care Model from the Patient-Centered Oncology Care® meeting.

Researchers have used positron emission tomography scans to identify which patients with a type of human epidermal growth factor receptor 2–positive breast cancer might benefit most from targeted agents alone and can be spared chemotherapy.

Employers are placing an increased focus on healthcare benefits and integrating or expanding healthcare offerings. With healthcare costs rising, employers are focusing not only on health plans but also on ways to improve employee experience with healthcare.

Patients of all ages see benefits with once-weekly carfilzomib compared with a twice-weekly dose, according to an analysis of the phase 3 A.R.R.O.W. trial.

Research comparing outcomes, resource utilization, and costs of multiple sclerosis (MS) found that patients with the disease face substantial burdens that differ among Japan, 5 European Union countries, and the United States.

Polypharmacy (patients taking ≥5 medications) is not uncommon in patients with relapsing-remitting multiple sclerosis and it is associated with higher levels of disability and the presence of comorbidities.

Breaking established habits and starting new, healthier ones can be difficult. However, patients, such as those with multiple sclerosis, can benefit from following strategies that help enact long-lasting healthy behaviors.

Minimal residual disease (MRD) is a strong prognosticator of cancer outcomes, and recent research found that patients with relapsed/refractory multiple myeloma (MM) are more likely to achieve MRD on daratumumab than on a standard of care alone.

Experts at the “Paying for Cures: Ensuring patient access and system sustainability" event discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time.

Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.

In the 30 days after the 2016 presidential election, demand for long-acting reversible contraceptives increased more than 20% compared with the same time the previous year.

The Caregiver Strain Index is a brief self-assessment tool that accurately measures the burden in caregivers of patients with multiple sclerosis.

During his second State of the Union address, President Trump highlighted past bipartisan accomplishments, such as legislation to confront the opioid crisis, but also outlined future priorities, such as addressing the cost of healthcare and prescription drugs.

Foundation Medicine announced that it has won a nationwide contract from the Department of Veterans Affairs National Precision Oncology Program. The contract covers all of Foundation Medicine’s tests.

ABIM Foundation is building upon its Choosing Wisely campaign with a new Trust Practice Challenge that will identify practices that build or rebuild trust in healthcare with the ultimate goal of creating a collection of replicable and scalable practices.

Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).